These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9551171)

  • 41. Synthesis of possible metabolites of 1-cyclopropyl-1,4-dihydro-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)- 4-oxo-3-quinolinecarboxylic acid (Grepafloxacin, OPC-17116).
    Morita S; Otsubo K; Matsubara J; Ohtani T; Kawano Y; Ohmori K; Ohguro K; Uchida M
    Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2246-52. PubMed ID: 8582026
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Difluoroquinolone lomefloxacin (Maxaquin): its role among fluoroquinolones, possibilities and prospectives].
    Padeĭskaia EN
    Antibiot Khimioter; 1998; 43(10):4-9. PubMed ID: 9825101
    [No Abstract]   [Full Text] [Related]  

  • 43. [Antimicrobial activity and action mechanism of ofloxacin].
    Padeĭskaia EN
    Antibiot Khimioter; 1996; 41(9):13-23. PubMed ID: 9005780
    [No Abstract]   [Full Text] [Related]  

  • 44. A review of clinical trials with fluoroquinolones with an emphasis on new agents.
    Blondeau JM
    Expert Opin Investig Drugs; 2000 Feb; 9(2):383-413. PubMed ID: 11060684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quinolone antibacterials. An update of their pharmacology and therapeutic use.
    von Rosenstiel N; Adam D
    Drugs; 1994 Jun; 47(6):872-901. PubMed ID: 7521829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. (Fluorocyclopropyl)quinolones. 2. Synthesis and Stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents.
    Kimura Y; Atarashi S; Kawakami K; Sato K; Hayakawa I
    J Med Chem; 1994 Sep; 37(20):3344-52. PubMed ID: 7932562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives.
    Bouzard D; Di Cesare P; Essiz M; Jacquet JP; Kiechel JR; Remuzon P; Weber A; Oki T; Masuyoshi M; Kessler RE
    J Med Chem; 1990 May; 33(5):1344-52. PubMed ID: 2329555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
    Mikamo H; Kawazoe K; Izumi K; Ito K; Tamaya T
    Drugs; 1995; 49 Suppl 2():326-30. PubMed ID: 8549350
    [No Abstract]   [Full Text] [Related]  

  • 49. [Comparative pharmacokinetics of lomefloxacin and other fluoroquinolones].
    Iakovlev VP
    Antibiot Khimioter; 1998; 43(10):46-52. PubMed ID: 9825111
    [No Abstract]   [Full Text] [Related]  

  • 50. The fluorinated quinolones.
    Kidwai M; Misra P; Kumar R
    Curr Pharm Des; 1998 Apr; 4(2):101-18. PubMed ID: 10197035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group.
    Jones RN; Sader HS; Erwin ME
    Diagn Microbiol Infect Dis; 1994 Oct; 20(2):93-8. PubMed ID: 7867311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breakpoint determination: rufloxacin.
    Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):574-5. PubMed ID: 8404928
    [No Abstract]   [Full Text] [Related]  

  • 53. [New fluoroquinolones and treatment of acute sinusitis].
    Gehanno P; Trémolières F
    Presse Med; 1999 Sep; 28(25):1365. PubMed ID: 10506868
    [No Abstract]   [Full Text] [Related]  

  • 54. [Effect of lomefloxacin on the functional activity of the phagocytic system].
    Mozhokina GN; Gracheva MP; Sokolova GB
    Antibiot Khimioter; 1996 Mar; 41(3):25-8. PubMed ID: 8967798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lomefloxacin disc susceptibility criteria--a reappraisal.
    Smith JM; Hashmi ZS
    J Antimicrob Chemother; 1990 Jul; 26(1):152-3. PubMed ID: 2211438
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacokinetics of enrofloxacin in chicken.
    Kan CA
    Br Poult Sci; 1997 Dec; 38(5):614. PubMed ID: 9511011
    [No Abstract]   [Full Text] [Related]  

  • 57. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Wadworth AN; Goa KL
    Drugs; 1991 Dec; 42(6):1018-60. PubMed ID: 1724637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quinolinecarboxylic acids. 3. Synthesis and antibacterial evaluation of 2-substituted-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de] [1,4]benzothiazine-6-carboxylic acids related to rufloxacin.
    Cecchetti V; Fravolini A; Pagella PG; Savino A; Tabarrini O
    J Med Chem; 1993 Oct; 36(22):3449-54. PubMed ID: 8230136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of lomefloxacin on the normal oral and intestinal microflora.
    Edlund C; Brismar B; Nord CE
    Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):35-9. PubMed ID: 2303064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potent non-6-fluoro-substituted quinolone antibacterials: synthesis and biological activity.
    Ledoussal B; Bouzard D; Coroneos E
    J Med Chem; 1992 Jan; 35(1):198-200. PubMed ID: 1732530
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.